# FDA 483 - Jeffrey R. Hoodin, M.D. - March 13, 2026

Source: https://www.keypedia.com/records/483/jeffrey-r-hoodin-md/820c03d3-99ac-45be-a0bd-70ecbffa20e7

> FDA 483 for Jeffrey R. Hoodin, M.D. on March 13, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Jeffrey R. Hoodin, M.D.
- Inspection Date: 2026-03-13
- Product Type: drugs
- Office Name: Denver District Office
- Summary: An FDA inspection of Jeffrey R. Hoodin, M.D. in Phoenix, AZ, identified significant non-compliance in a clinical investigation. The principal investigator failed to maintain adequate and accurate case histories, including issues with unauthorized personnel reviewing assessments, conflicting documentation, and delayed eligibility determinations. Furthermore, the firm enrolled ineligible subjects and did not adhere to protocol requirements for managing concomitant medications.

## Related Documents

- [483 - 2026-03-13](https://www.keypedia.com/records/483/jeffrey-r-hoodin-md/ce3f1be8-c32d-4be0-a803-e3dc2b60bbca)

## Related Officers

- [Andra Lepnis](https://www.keypedia.com/people/andra-lepnis/38811302-3d96-427a-955d-c4c42de05a7c)
- [Lan T. Tran](https://www.keypedia.com/people/lan-t-tran/ab9c1008-c03f-425f-ac3c-a569d3e5037c)

Company: https://www.keypedia.com/companies/jeffrey-r-hoodin-md/71a8d83c-0100-41ac-82c6-e476d24789c1

Office: https://www.keypedia.com/offices/denver-district-office/93b79063-390c-4759-af6c-5da7e388face